Analysts See 22% Gains Ahead For The Holdings of JQUA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2025
0mins
Should l Buy QGEN?
Source: NASDAQ.COM
JPMorgan US Quality Factor ETF Analysis: The JPMorgan US Quality Factor ETF (JQUA) has an implied analyst target price of $66.47 per unit, indicating a potential upside of 21.58% from its current trading price of $54.67.
Notable Holdings with Upside Potential: Key underlying holdings such as Madison Square Garden Sports Corp, Qiagen NV, and Zscaler Inc show significant upside potential based on analysts' target prices, raising questions about the validity of these targets amidst market developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QGEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QGEN
Wall Street analysts forecast QGEN stock price to fall
14 Analyst Rating
8 Buy
6 Hold
0 Sell
Moderate Buy
Current: 50.850
Low
45.00
Averages
50.57
High
55.00
Current: 50.850
Low
45.00
Averages
50.57
High
55.00
About QGEN
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
QIAGEN NV: TD Cowen Increases Price Target from $48 to $53
Target Price Increase: The target price for a specific stock has been raised to $53 from a previous $48.
Market Reaction: This adjustment reflects a positive outlook on the company's performance and potential growth.
See More
Qiagen Reports Strong Q4 2025 Earnings Exceeding Expectations
- Performance Exceeds Expectations: Qiagen reported net sales of $540 million in Q4 2025, growing 1% year-over-year, with adjusted EPS at $0.62, both surpassing company forecasts, indicating robust market performance.
- Growth Pillars Performance: The combined sales from Sample Technologies, QuantiFERON, QIAstat, QIAcuity, and QIAGEN Digital Insights reached $1.49 billion, reflecting an 8% increase, underscoring the sustained growth of its core business and enhancing competitive positioning.
- Cash Flow and Shareholder Returns: Free cash flow was $453 million, with over $1.1 billion returned to shareholders since 2024, demonstrating strong capital management and investment capabilities, alongside the introduction of an annual dividend to attract investors.
- Future Outlook: Management anticipates at least 5% sales growth and adjusted EPS of at least $2.50 for 2026, despite challenges from macroeconomic uncertainty and cautious customer spending, with new product launches expected to accelerate performance in the second half of the year.
See More
Qiagen Reports Q4 Net Income Growth
- Net Income Growth: Qiagen's Q4 net income rose to $107.83 million, translating to $0.49 per share, up from $88.32 million and $0.39 per share last year, indicating enhanced profitability.
- Sales Increase: The quarter's net sales reached $540.42 million, an increase from $521.20 million last year, surpassing analysts' expectations of $528.49 million, reflecting sustained market demand.
- Future Outlook: Qiagen anticipates at least a 1% increase in Q1 2026 net sales to $483 million, with adjusted EPS expected at $0.54, despite the dilutive impacts from the Parse acquisition and tariffs, showcasing confidence in future growth.
- Annual Projections: The company expects at least a 5% growth in net sales for 2026, reaching $1.64 billion, with adjusted EPS projected at $2.50, highlighting strategic decisions in ongoing investments and market expansion.
See More
Qiagen Q4 Earnings Beat Expectations with Revenue Growth
- Strong Earnings: Qiagen reported a Q4 non-GAAP EPS of $0.62, aligning with market expectations, indicating stability in the company's profitability.
- Revenue Growth: The company achieved Q4 revenue of $540 million, a 3.6% year-over-year increase, beating market expectations by $11.51 million, reflecting sustained demand for its products.
- 2026 Outlook: Qiagen anticipates at least 5% net sales growth in 2026, with growth pillars expected to contribute approximately $1.64 billion, although this is below the $2.21 billion consensus, highlighting future growth challenges.
- Stock Reaction: Despite the strong earnings report, Qiagen's shares fell by 3.7%, possibly reflecting market caution regarding future growth expectations.
See More
Qiagen Reports Strong Q4 Earnings Exceeding Expectations
- Strong Earnings Performance: Qiagen reported a net income of $107.8 million for Q4, with earnings per share at $0.49 and adjusted earnings at $0.62, meeting Wall Street expectations and demonstrating stable profitability.
- Revenue Exceeds Expectations: The company posted revenue of $540.4 million in the quarter, surpassing analyst forecasts of $528 million, indicating strong demand for its diagnostic products and an increase in market share.
- Impressive Annual Results: For the year, Qiagen achieved a profit of $424.9 million, or $1.94 per share, with total revenue reaching $2.09 billion, reflecting healthy growth across its business segments.
- Increased Market Confidence: The alignment of Q4 results with expectations may bolster analyst optimism regarding Qiagen's future performance, potentially driving its stock price higher and enhancing investor confidence.
See More
Qiagen Set to Announce Q4 Earnings on February 4th
- Earnings Announcement: Qiagen is set to release its Q4 earnings on February 4th after market close, with a consensus EPS estimate of $0.62, reflecting a 1.6% year-over-year growth, indicating stable profitability.
- Revenue Expectations: The anticipated revenue for Q4 is $528.49 million, representing a 1.4% year-over-year increase, although facing downward revisions, it still suggests some growth potential.
- Performance Beat Record: Over the past two years, Qiagen has beaten EPS estimates 63% of the time and revenue estimates 88% of the time, showcasing its competitive edge and execution capabilities in the market.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and seven downward revisions, while revenue estimates experienced no upward revisions and nine downward revisions, reflecting a cautious market outlook on the company's future performance.
See More
QIAGEN NV: TD Cowen Increases Price Target from $48 to $53
Target Price Increase: The target price for a specific stock has been raised to $53 from a previous $48.
Market Reaction: This adjustment reflects a positive outlook on the company's performance and potential growth.
See More
Qiagen Reports Strong Q4 2025 Earnings Exceeding Expectations
- Performance Exceeds Expectations: Qiagen reported net sales of $540 million in Q4 2025, growing 1% year-over-year, with adjusted EPS at $0.62, both surpassing company forecasts, indicating robust market performance.
- Growth Pillars Performance: The combined sales from Sample Technologies, QuantiFERON, QIAstat, QIAcuity, and QIAGEN Digital Insights reached $1.49 billion, reflecting an 8% increase, underscoring the sustained growth of its core business and enhancing competitive positioning.
- Cash Flow and Shareholder Returns: Free cash flow was $453 million, with over $1.1 billion returned to shareholders since 2024, demonstrating strong capital management and investment capabilities, alongside the introduction of an annual dividend to attract investors.
- Future Outlook: Management anticipates at least 5% sales growth and adjusted EPS of at least $2.50 for 2026, despite challenges from macroeconomic uncertainty and cautious customer spending, with new product launches expected to accelerate performance in the second half of the year.
See More
Qiagen Reports Q4 Net Income Growth
- Net Income Growth: Qiagen's Q4 net income rose to $107.83 million, translating to $0.49 per share, up from $88.32 million and $0.39 per share last year, indicating enhanced profitability.
- Sales Increase: The quarter's net sales reached $540.42 million, an increase from $521.20 million last year, surpassing analysts' expectations of $528.49 million, reflecting sustained market demand.
- Future Outlook: Qiagen anticipates at least a 1% increase in Q1 2026 net sales to $483 million, with adjusted EPS expected at $0.54, despite the dilutive impacts from the Parse acquisition and tariffs, showcasing confidence in future growth.
- Annual Projections: The company expects at least a 5% growth in net sales for 2026, reaching $1.64 billion, with adjusted EPS projected at $2.50, highlighting strategic decisions in ongoing investments and market expansion.
See More
Qiagen Q4 Earnings Beat Expectations with Revenue Growth
- Strong Earnings: Qiagen reported a Q4 non-GAAP EPS of $0.62, aligning with market expectations, indicating stability in the company's profitability.
- Revenue Growth: The company achieved Q4 revenue of $540 million, a 3.6% year-over-year increase, beating market expectations by $11.51 million, reflecting sustained demand for its products.
- 2026 Outlook: Qiagen anticipates at least 5% net sales growth in 2026, with growth pillars expected to contribute approximately $1.64 billion, although this is below the $2.21 billion consensus, highlighting future growth challenges.
- Stock Reaction: Despite the strong earnings report, Qiagen's shares fell by 3.7%, possibly reflecting market caution regarding future growth expectations.
See More
Qiagen Reports Strong Q4 Earnings Exceeding Expectations
- Strong Earnings Performance: Qiagen reported a net income of $107.8 million for Q4, with earnings per share at $0.49 and adjusted earnings at $0.62, meeting Wall Street expectations and demonstrating stable profitability.
- Revenue Exceeds Expectations: The company posted revenue of $540.4 million in the quarter, surpassing analyst forecasts of $528 million, indicating strong demand for its diagnostic products and an increase in market share.
- Impressive Annual Results: For the year, Qiagen achieved a profit of $424.9 million, or $1.94 per share, with total revenue reaching $2.09 billion, reflecting healthy growth across its business segments.
- Increased Market Confidence: The alignment of Q4 results with expectations may bolster analyst optimism regarding Qiagen's future performance, potentially driving its stock price higher and enhancing investor confidence.
See More
Qiagen Set to Announce Q4 Earnings on February 4th
- Earnings Announcement: Qiagen is set to release its Q4 earnings on February 4th after market close, with a consensus EPS estimate of $0.62, reflecting a 1.6% year-over-year growth, indicating stable profitability.
- Revenue Expectations: The anticipated revenue for Q4 is $528.49 million, representing a 1.4% year-over-year increase, although facing downward revisions, it still suggests some growth potential.
- Performance Beat Record: Over the past two years, Qiagen has beaten EPS estimates 63% of the time and revenue estimates 88% of the time, showcasing its competitive edge and execution capabilities in the market.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and seven downward revisions, while revenue estimates experienced no upward revisions and nine downward revisions, reflecting a cautious market outlook on the company's future performance.
See More
